TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02949440

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the caudal-to-cranial approach
Description: Cutting the peritoneum along the line between the right mesocolon and retroperitoneum, enter the Toldt's space to dissect the posterior of Superior mesenteric vein and Superior mesenteric artery and their branches, and then finished the D3 dissection from caudal to cranial on both sides of the mesentery along the Superior mesenteric vein. In the end, cut the lateral ligament to mobilize the posterior space of ascending colon. This approach is called the caudal-to-cranial approach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the medial-to-lateral approach
Description: First, the pedicle of ileocolic vessels is identified and the mesocolon is dissected between the pedicle and the periphery of the Superior mesenteric vein to expose the second portion of the duodenum. The ileocolic vessels are then cut at their roots. The ascending mesocolon is separated from the retroperitoneal tissues, duodenum, and pancreatic head up to the hepatocolic ligament cranially. The important detail in this procedure is the wide separation between the pancreatic head and the transverse mesocolon.This approach is the medial-to-lateral(MtL) approach
Study: NCT02457221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: oral
Study: NCT02300662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycle Ergometer
Description: Passive movement of the cycle ergometer will execute alternate flexions and extensions of the patients' knee and hips bilaterally for 20 minutes consecutively.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional physiotherapy
Description: Manual bronchial hygiene exercises: vibrocompression, manoeuvres with a manual resuscitator (bag squeezing) and aspiration of secretions where necessary.
Study: NCT01723332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational
Description: The first interaction will happen at study enrolment and will be educational in nature.~Following the session, the nurse will follow up with the participant to discuss any questions.
Study: NCT00882947

Intervention type: DRUG
Intervention: Ventavis (Iloprost, BAYQ6256)
Description: Iloprost solution for inhalation, BAYQ6256, Synthetic Prostacyclin analog
Study: NCT01723332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self management
Description: The second interaction will take place 2 months after enrollment and will focus on self management and communication skills.~Following the session, the nurse will follow up with the participant to discuss any questions.
Study: NCT04663048

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PiXL
Description: Phototherapeutic intrastromal corneal collagen cross-linking (PiXL) performed in a high-oxygen environment without corneal epithelial debridement, for treatment of low grade myopia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PiXL
Description: Phototherapeutic intrastromal corneal collagen cross-linking (PiXL) performed in a high-oxygen environment without corneal epithelial debridement, for treatment of low grade myopia.
Study: NCT01786967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine Fumarate
Description: FDA approved anticholinergic medication used for treatment of urge urinary incontinence
Study: NCT02466022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Bolus dose prior to spinal anesthetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivicaine
Description: Intrathecal hyperbaric bupivicaine 12.75mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivicaine
Description: Intrathecal hyperbaric bupivicaine 12.75mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Bolus 0.1cc/kg Normal Saline over 10 min
Study: NCT02300662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: Manual bronchial hygiene exercises: vibrocompression, manoeuvres with a manual resuscitator (bag squeezing) and aspiration of secretions where necessary.
Study: NCT04476693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast consumption
Description: Consumption of breakfast: The breakfast provided was designed based on the characteristics of an ideal breakfast outlined in Giovannini et al., (2008). The breakfast provided in the present study will include the following: all-bran cereals (Kellogg's), semi-skimmed milk (Tesco), Royal Gala Apple (Tesco) and Orange Juice from Concentrate (Tesco) containing the amount of carbohydrates usually consumed at breakfast in the UK (Reeves et al., 2013). The portion for each participant will contain 0.06 g of carbohydrate per kcal of measured RMR. As the portion size (20% of daily calorie intake) will be calculated based on individual RMR , no leftovers will be allowed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast Omission
Description: Omission of breakfast. Participants will consume water within 15 min, the individual volume of which will be calculated based on the liquid content of the breakfast \[milk (ml)+ orange juice (ml)\].
Study: NCT03327727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Agent: VL-2397
Description: VL-2397

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B
Description: Voriconazole, Isavuconazole, or Liposomal amphotericin B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B
Description: Voriconazole, Isavuconazole, or Liposomal amphotericin B
Study: NCT02466022

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Bolus 0.1cc/kg Normal Saline over 10 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Intrathecal Fentanyl 10ug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: Intrathecal Fentanyl 10ug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 0-4mg of IV Midazolam prn for rescue sedation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: 0-4mg of IV Midazolam prn for rescue sedation
Study: NCT01428648

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ballroom Dancing Classes
Description: bi-weekly, 12-Week ballroom dance classes
Study: NCT02669888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indigo naturalis ointment
Description: Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.
Study: NCT00853203

Intervention type: BEHAVIORAL
Intervention: Interviews
Description: Open-ended Interviews, audiotaped, lasting 30 minutes to 1 hour.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Written survey taking about 1 hour.
Study: NCT04091139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified protocol for adolescents (UP-A)
Description: The Unified Protocol (UP) is an emotion-focused, cognitive-behavioural intervention that is developed to target core temperamental characteristics underlying anxiety and depressive disorders. The goal of the UP is to help patients to cultivate a greater willingness to experience uncomfortable emotions and to reduce maladaptive emotion response tendencies, so as to lessen the intensity and frequency of uncomfortable emotions. Ehrenreich and colleagues modified from the original UP and developed the UP for adolescents (UP-A).~A Chinese treatment protocol would be developed based on the UP-A. Contents of the treatment includes motivational enhancement, psychoeducation of emotion, avoidance and emotion driven behaviours, interoceptive exposure, cognitive reappraisal, emotion awareness training and emotion exposure. It consists of 10 to 12 individual sessions for the adolescents, and 4 to 6 sessions for parents or guardians.
Study: NCT00853203

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Written survey taking about 1 hour.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Written survey taking about 1 hour.

Intervention type: OTHER
Intervention: Electronically Activated Recorder (EAR)
Description: Recording system (a digital tape-recorder and small external microphone) programmed to record for 30 seconds every 12 minutes, repeating over two consecutive days of wearing.

Intervention type: BEHAVIORAL
Intervention: Group Meetings
Description: 12 Audiotaped Group Meetings over 4 months: 9 weekly meetings, 2 semi-monthly (twice a month) meetings, and a final meeting in month 4. Each meeting will last 1 hour.

Intervention type: BEHAVIORAL
Intervention: Written Materials
Description: Written educational materials plus community resource information.

Intervention type: BEHAVIORAL
Intervention: Written Materials
Description: Written educational materials plus community resource information.
Study: NCT04562714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre Flash Glucose Monitor
Description: The FreeStyle Libre FGM device consists of a skin-worn disposable sensor that automatically measures and continuously stores glucose readings. The sensor is placed by a single-use applicator and is activated by a wireless scan with a handheld reader. It is designed to stay on the body for up to 14 days, and can be worn under clothing. After a 1-hour warm-up period, the sensor takes automatic measurements of glucose every 15 minutes for up to 14 days. The device collects the interstitial glucose values and stores them for subsequent upload at the end of the 14-day wear period. With each scan, users receive their glucose reading; the last eight hours of glucose data; and an arrow illustrating the direction their glucose is heading.

Intervention type: OTHER
Group type: OTHER
Intervention: Diabetes self-management education
Description: The DSME curriculum is compromised of:~1. Review of weekly glucose report (Trend glucose report from Libreview for intervention group; and weekly glucose report in log book format from their glucose monitoring software for control group)~2. Education modules for both in-person and remote delivery;~3. Handouts to support the curriculum objectives; and~4. Blood glucose monitoring challenges to stimulate behaviour change and reinforce learning.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes self-management education
Description: The DSME curriculum is compromised of:~1. Review of weekly glucose report (Trend glucose report from Libreview for intervention group; and weekly glucose report in log book format from their glucose monitoring software for control group)~2. Education modules for both in-person and remote delivery;~3. Handouts to support the curriculum objectives; and~4. Blood glucose monitoring challenges to stimulate behaviour change and reinforce learning.
Study: NCT04091139

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: TAU participants will receive usual clinical psychological service provided in the clinic (i.e. treatment as usual) in the first 12 weeks, before they start receiving same individual treatment program based on UP-A.
Study: NCT02235493

Intervention type: BIOLOGICAL
Intervention: Retrospective Case Only
Study: NCT05462665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: theory training
Description: theory training
Study: NCT00593684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver Alginate
Description: This is a sterile patch of polyurethane foam coated with silver alginate and maltodextrin matrix that is impregnated with 141 mg of ionic silver per 100 cm2.
Study: NCT05462665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: theory training
Description: theory training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: theory and simulation training
Description: theory and simulation training
Study: NCT01935817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg complex

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02437591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fidaxomicin
Description: oral
Study: NCT04101643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evolocumab
Description: Eligible patients receive subcutaneous injections of evolocumab 420 mg
Study: NCT04584060

Intervention type: COMBINATION_PRODUCT
Intervention: ERAS protocols
Description: ERAS protocols including avoidance of prolonged pre-operative fasting and early removal of Ryle, surgical drains and urinary catheter

Intervention type: COMBINATION_PRODUCT
Intervention: Early oral feeding
Description: Chewing gum, oral magnesium and alvimopan can be started early postoperatively, Initiation of feeding-Oral sips on day 1, step up day 2 onward

Intervention type: COMBINATION_PRODUCT
Intervention: Prophylaxis against DVT
Description: Patient will wear well-fitting compression stockings and receive pharmacological prophylaxis with LMWH. Encourage to mobilize out of bed after effect of general anesthesia has weaned off.
Study: NCT03936855

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct composite resin
Description: For both groups: The teeth will have the enamel surface conditioned with 37% phosphoric acid. For the restorative procedure, the same adhesive system will be used~GROUP ACTIVE COMPARATOR~1. Insert resin-modified glass ionomer cement into the pulp chamber;~2. Complete the restoration by incremental technique using conventional composite resin in increments of 2mm;~EXPERIMENTAL GROUP~1. Insert Bulk Fill composite inside the pulp chamber to the height of 5 mm;~2. Complete the insertion of the Bulk Fill resin to the limit of the caval surface angle in the occlusal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct composite resin
Description: For both groups: The teeth will have the enamel surface conditioned with 37% phosphoric acid. For the restorative procedure, the same adhesive system will be used~GROUP ACTIVE COMPARATOR~1. Insert resin-modified glass ionomer cement into the pulp chamber;~2. Complete the restoration by incremental technique using conventional composite resin in increments of 2mm;~EXPERIMENTAL GROUP~1. Insert Bulk Fill composite inside the pulp chamber to the height of 5 mm;~2. Complete the insertion of the Bulk Fill resin to the limit of the caval surface angle in the occlusal
Study: NCT02820623

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-report

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chart-Stimulated Recall

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Rehearsal
Study: NCT03269149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Tango Dance
Description: 20 improvisational, 90-minute adapted tango dance sessions over a 12-week period. Classes begin with a 20-minute standing warm-up followed by partnering and rhythmic exercises. Next, novel step elements are introduced and participants will be taught how to combine the new steps with previously learned steps via improvisation. Caregivers will dance with each other or undergraduate /graduate student volunteers. Music will be played throughout classes and artistic expression, i.e., attention to aesthetics, and improvisation, will be encouraged.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational lectures
Description: Participants will take part in at least 20 educational lectures offered twice per week over 12 weeks. Classes will also be 1.5 hours long and will involve lecture, partnered and group learning and extensive Q\&A will be encouraged.
Study: NCT00889733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) Cisplatin
Description: For patients who have had neoadjuvant chemotherapy followed by optimal debulking surgery they go on to receive combined IP Cisplatin and IV Paclitaxel.
Study: NCT02842125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ad-P53
Description: Adenoviral Investigational Product Ad-P53 to treat metastases using an intra-arterial catheter, with oral metronomic capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ad-P53
Description: Adenoviral Investigational Product Ad-P53 to treat metastases using an intra-arterial catheter, with oral metronomic capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ad-P53
Description: Adenoviral Investigational Product Ad-P53 to treat metastases using an intra-arterial catheter, with oral metronomic capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: Oral metronomic chemotherapeutic agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keytruda
Description: Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opdivo
Description: Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors
Study: NCT00675519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy
Description: Motivational enhancement therapy begins with the assumption that the responsibility and capacity for change lie within the client. The therapist begins by providing individualized feedback about the effects of the patient's drinking. Working closely together, therapist and patient explore the benefits of abstinence, review treatment options, and design a plan to implement treatment goals.
Study: NCT03711825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYN-057
Description: Administration of single dose of LYN-057 presented as extended release capsule containing 50 mg of memantine hydrochloride (HCl)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging Assessment (MRI)
Description: Imaging assessments \[MRI\] will be performed on specified days according to protocol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging Assessment (U/S)
Description: Imaging assessments (abdominal U/S) will be performed on specified days according to protocol
Study: NCT01256372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP214
Description: AP214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP214
Description: AP214

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo; intravenous infusion
Study: NCT02281214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample, biopsy
Description: Blood samples and tumor biopsies will taken from patients before treatment and when tumor progression on therapy for Next Generation Sequencing (NGS) mutation analysis
Study: NCT02490878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: IV
Study: NCT02931240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revivent TC
Description: Treatment of LV scar
Study: NCT02727647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FVIII
Description: FVIII concentration 35-40 U/kg/dose 1 time/week for 5 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FVIII
Description: FVIII concentration 15-20 U/kg/dose 1 time/week for 5 months
Study: NCT02431832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Augmentin tab
Study: NCT01114217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: IV Ferumoxytol
Study: NCT02213224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril
Description: Perindopril is a kind of angiotensin converting enzyme inhibitors (ACEIs) which has been considered as the first-line drugs for the treatment of hypertension and has been proved safe during the widespread use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Telmisartan is a kind of angiotensin receptor blockers (ARBs) which has also been considered as the first-line drugs for the treatment of hypertension and has been proved safe during the widespread use.
Study: NCT00684320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Disengagement Training (ADT)
Description: Those assigned to ADT condition will receive a computer delivered attention retraining protocol designed to enhance attention disengagement from socially threatening stimuli. The ADT protocol includes eight 30-min sessions delivered over a 6-week period (i.e., bi-weekly sessions). During each session, participants will see 320 trials that consist of the various combinations of probe type (E or F) probe position (top or bottom), and emotion type (Neutral, Disgust, Anger). 256 trials will include one neutral face and one disgust face or one angry face: 2 (probe type) X 2 (probe position) X 16 (person) X 4 (repetitions). On trials where participants see one neutral face and one disgust or angry face (i.e., 80% of the trials), the probe will always follow the neutral face.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Condition
Description: The placebo condition (PC) will be identical to the AMP condition except that during the presentation of the trials where a threat picture is present, the probe will appear with equal frequency in the position of threat and neutral pictures. Thus, neither threat nor neutral pictures have signal value with regard to the position of the probe.
Study: NCT02213224

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine is also a kind of widely used first-line drugs for the treatment of hypertension, and there is no evidence showing that it is effective for NAFLD.
Study: NCT04538534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicardipine
Description: To compare the association of nicardipine and isosorbide dinitrate vs isosorbide dinitrate alone on the rate of occurrence of radial artery spasm
Study: NCT01792258

Intervention type: PROCEDURE
Intervention: Percutaneous tracheostomy
Description: Percutaneous tracheostomies will be performed with the kit commercially available in the current clinical practice.
Study: NCT00669955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole, amoxicillin, clarithromycin
Description: Triple therapy given for 7 days at a dose of omeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pylera (Bismuth subcitrate potassium, metronidazole, tetracycline) given in combination with omeprazole
Description: Pylera is a three in one capsule containing bismuth subcitrate potassium 120 mg, metronidazole 125 mg and tetracycline 125 mg given as 3 capsules QID, with omeprazole 20 mg BID.
Study: NCT02943681

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles vaccine